111 related articles for article (PubMed ID: 23211696)
21. [Mastocytosis, classification, biological diagnosis and therapy].
Arock M
Ann Biol Clin (Paris); 2004; 62(6):657-69. PubMed ID: 15563424
[TBL] [Abstract][Full Text] [Related]
22. Mast cell sarcoma: clinical management.
Weiler CR; Butterfield J
Immunol Allergy Clin North Am; 2014 May; 34(2):423-32. PubMed ID: 24745684
[TBL] [Abstract][Full Text] [Related]
23. Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia.
Chantorn R; Shwayder T
Pediatr Dermatol; 2012; 29(5):605-9. PubMed ID: 22329485
[TBL] [Abstract][Full Text] [Related]
24. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
25. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
26. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
28. Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications.
Ryan RJ; Akin C; Castells M; Wills M; Selig MK; Nielsen GP; Ferry JA; Hornick JL
Mod Pathol; 2013 Apr; 26(4):533-43. PubMed ID: 23196796
[TBL] [Abstract][Full Text] [Related]
29. Malignant systemic mastocytosis.
Abraham EK; Augustine J; Amma S; Nair K
Indian J Cancer; 1992 Dec; 29(4):192-7. PubMed ID: 1293004
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic mast cell sarcoma: a unique pathologic entity in mastocytosis.
He F; Horny HP; Boone J; Raza A; Griffith M; Hurley P; Dolan M; Cayci Z; Linden MA; McKenna R; Ustun C
Leuk Lymphoma; 2017 Jun; 58(6):1515-1517. PubMed ID: 27808598
[No Abstract] [Full Text] [Related]
31. [Systemic mastocytosis. A review of current diagnostic and therapeutic approaches].
Pari F; Zamagni MD; Carnevali C; Pagani M; Rabbi C; Cantore M; Cavazzini G; Aitini E; Smerieri F
Recenti Prog Med; 1999 Mar; 90(3):169-72. PubMed ID: 10228358
[TBL] [Abstract][Full Text] [Related]
32. The first report of human primary thoracic spine mast cell sarcoma: a case report.
Ravanpay AC; Fromm JR; Edlefsen KL; Martin P; Chesnut R
Clin Neuropathol; 2018; 37(1):28-35. PubMed ID: 28992848
[TBL] [Abstract][Full Text] [Related]
33. Proliferation of reactive and neoplastic human tissue mast cells. An immunohistochemical study using the antibody PC10 (anti-PCNA).
Horny HP; Schumacher U; McCullagh P; Wehrmann M; Roche WR; Kaiserling E
J Pathol; 1993 Jul; 170(3):265-70. PubMed ID: 7907655
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase.
Tsujimura T; Kanakura Y; Kitamura Y
Leukemia; 1997 Apr; 11 Suppl 3():396-8. PubMed ID: 9209403
[TBL] [Abstract][Full Text] [Related]
35. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.
Zappulla JP; Dubreuil P; Desbois S; Létard S; Hamouda NB; Daëron M; Delsol G; Arock M; Liblau RS
J Exp Med; 2005 Dec; 202(12):1635-41. PubMed ID: 16352739
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
37. Canine extracutaneous mast-cell tumours consisting of connective tissue mast cells.
Iwata N; Ochiai K; Kadosawa T; Takiguchi M; Umemura T
J Comp Pathol; 2000 Nov; 123(4):306-10. PubMed ID: 11042002
[TBL] [Abstract][Full Text] [Related]
38. Solitary mastocytoma of infancy.
Kilburn HL
Clin Pediatr (Phila); 1974 Jan; 13(1):60-2. PubMed ID: 4203516
[No Abstract] [Full Text] [Related]
39. A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone.
Baghestanian M; Bankl Hc; Sillaber C; Beil WJ; Radaszkiewicz T; Füreder W; Preiser J; Vesely M; Schernthaner G; Lechner K; Valent P
Leukemia; 1996 Jan; 10(1):159-66. PubMed ID: 8558922
[TBL] [Abstract][Full Text] [Related]
40. [Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis].
Horny HP; Krokowski M; Feller AC; Hintze G; Sotlar K; Valent P
Wien Klin Wochenschr; 2002 Mar; 114(5-6):222-8. PubMed ID: 12238313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
